FDA Approves Baxter's PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement TherapyJanuary 21, 2015 8:15 am | News | Comments
Baxter International has announced the FDA has approved PHOXILLUM Renal Replacement Solutions as replacement solutions in continuous renal replacement therapy to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances.
Baxter announced it voluntarily initiated a recall in the United States of two lots of 0.9%...
Pfizer has completed the acquisition of Baxter International Inc.’s portfolio of marketed...
Mylan has confirmed that it and several subsidiaries have been sued by several Baxter...
SAFC will contribute extensive expertise in conjugation and the manufacture of drug linkers, while BioPharma Solutions will offer world-class, sterile fill/finish services for final filling of ADC products.
Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''
Baxter International Inc. announced today it is voluntarily recalling one lot of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826 to the hospital/pharmacy/nurse level. The recall is being initiated due to a labeling error on the shipping cartons in a single lot, which was identified by three customers.
Baxter International and Halozyme Therapeutics announced that the FDA approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
Baxter International has announced that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.
Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.
Baxter International Inc. announces the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).
Baxter International has announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products.
The recall is being initiated as a result of complaints of particulate matter, identified as mold, resulting from a leak in the container.
Baxter International has restructured its ongoing agreement with Xenetic Biosciences, for the development of BAX 826, a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness.
Baxter International Inc. has initiated a voluntary recall in the United States of two lots of CLINIMIX and one lot of CLINIMIX E Injection parenteral nutrition products to the user level due to complaints of particulate matter found in the products
Cell Therapeutics and Baxter International announced a partnership on Cell Therapeutics' drug pacritinib, a potential treatment for the bone marrow disease myelofibrosis. Cell Therapeutics said it could get as much as $172 million in payments from Baxter, and the companies will split the profits on U.S. sales if the drug is approved.
Baxter International Inc. today posted solid financial results for the third quarter which met expectations as the company further augmented its portfolio with the acquisition of Gambro AB, and continued to advance its new product pipeline by launching new products, achieving multiple regulatory milestones, and establishing new collaborations.
Baxter International Inc. has initiated a voluntary recall of two lots of its Dual Luer Lock Caps (Product Code 2C6250, Lots 10043 and 10044) because of the presence of loose particulate matter found in the packaging. Particulate matter entering the fluid path from the Luer Lock Caps may result in thrombotic and embolic events, including: pulmonary embolism, myocardial infarction and stroke.
Baxter International Inc. has closed on its approximately $3.9 billion acquisition of Swiss dialysis products company Gambro AB. In July the European Union's antitrust authority cleared Baxter's bid for privately held Gambro.
The European Union's antitrust authority has cleared Baxter's proposed $2.76B takeover bid of Sweden's dialysis products firm Gambro.
Baxter International has announced solid financial results for the second quarter, with earnings that exceeded the company’s previously issued guidance, and confirmed its full-year 2013 financial outlook.
In yet another setback for the treatment of Alzheimer’s disease, Baxter said that a promising new therapy had failed to halt the mental decline caused by the disease in a late-stage clinical trial. Prospects that the drug might have some effect brightened last year when researchers reported that four patients who had received the maximum dose had gone three years without any decline in several measures of cognition and daily functioning,
In early February, a development agency in Minnesota’s Gov. Mark Dayton's administration made a deal with a giant pharmaceutical company: The state would explore grants and tax breaks that could yield almost 200 high-wage jobs all while keeping Baxter Healthcare Group's name out of the public conversation.
State leaders stand ready to commit up to $15.4 million in taxpayer subsidies to a Fortune 500 pharmaceutical company they hope will put an outpost in Minnesota, according to a document made public Wednesday. After declining to provide details the day before, Gov. Mark Dayton's office released a February letter from the governor and top legislators to a site hunter for Baxter Healthcare Corp.
Baxter International Inc. has closed its acquisition of a potential hemophilia treatment from the French drugmaker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $180 million. Baxter had said in January it agreed to buy the drug, labeled OBI-1, and related manufacturing operations.
Baxter International Inc. is laying off 400 workers at a pharmaceutical plant in Puerto Rico. The company is one of the largest employers in the central mountain town of Aibonito, where the plant is located. The executive director of the island's Industrial Development Company says the layoffs will be gradual and that the agency will help find jobs for displaced workers.
Baxter Provides Financial Outlook For 2013
DEERFIELD, Ill., January 24, 2013 - Baxter International Inc. (NYSE:BAX) announced today that it has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including...
St. Joseph's/Candler Health System in Savannah, Ga. Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community ServiceJanuary 23, 2013 4:22 am | by Baxter Healthcare | News | Comments
CHICAGO, January 23, 2013 - In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, St. Joseph's/Candler Health System in Savannah, Ga. is the recipient of the 2012 Foster G. McGaw Prize for Excellence in Community...
- Page 1